At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Successful Treatment Outcomes of Dexamethasone Cyclophosphamide Pulse (DCP) Therapy and Dexamethasone Azathioprine Pulse (DAP) Therapy in Pemphigus Vulgaris Patients At a Tertiary Care Hospital, Karachi
In Brief
A Phase 4 clinical trial evaluating Dexamethasone Cyclophosphamide Pulse therapy and Dexamethasone Azathioprine Pulse therapy for Pemphigus Vulgaris. Completed, enrolled 66 participants across 1 site.
Detailed Summary
What's the study about? This study focused on comparing two different treatments for pemphigus vulgaris, a skin condition caused when body's immune system works against itself. The treatments were dexamethasone cyclophosphamide pulse (DCP) therapy and dexamethasone azathioprine pulse (DAP) therapy. Why was this study done? The goal of the study was to determine which treatment, DCP or DAP, was more effective in treating pemphigus vulgaris. Both treatments involve high-dose steroids combined with other medications, but they differ in the specific medications used. How did they do the study? Researchers conducted a randomized controlled trial, where patients were randomly assigned to receive either DCP or DAP therapy. They then followed these patients to see how well each treatment worked.
Study Details
Timeline
Interventions
33 patients were enrolled in DCP group. They were given Dexamethasone Cyclophosphamide pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
33 patients were enrolled in DAP group. They were given Dexamethasone Azathioprine pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.